Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
- DOI
- 10.25405/ncl.34667028.v1
- Published
- 2026
- Container
- Not recorded
- Publisher
- Newcastle University
- Open access
- no
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- supportingPublication license: A publication license was supplied: https://rightsstatements.org/page/InC/1.0/?language=en. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.25405/ncl.34667028.v1,
title = {Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study},
author = {D Serin and M Verrill and A Jones and T Delozier and R Coleman and ED Kreuser and K Mross and B Longerey and M Brandely},
year = {2026},
doi = {10.25405/ncl.34667028.v1},
url = {https://doi.org/10.25405/ncl.34667028.v1}
}RIS
TY - JOUR TI - Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study AU - D Serin AU - M Verrill AU - A Jones AU - T Delozier AU - R Coleman AU - ED Kreuser AU - K Mross AU - B Longerey AU - M Brandely PY - 2026 DO - 10.25405/ncl.34667028.v1 UR - https://doi.org/10.25405/ncl.34667028.v1 ER -
APA
Serin, D., Verrill, M., Jones, A., Delozier, T., Coleman, R., Kreuser, E., Mross, K., Longerey, B., & Brandely, M. (2026). Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. https://doi.org/10.25405/ncl.34667028.v1
Source records
- datacite · retrieved 2026-11-10T12:34:29.023Z